Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
CEO： Mr. Peter Fernandes
Listing Date： 02/13/2015